D
Dianthus Therapeutics, Inc. (DNTH)
NCM – Real vaqt narxi. Valyuta: USD
86.15
-0.97 (-1.11%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
86.15
-0.97 (-1.11%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Dianthus Therapeutics, Inc. klinik bosqichdagi biotexnologiya kompaniyasi bo'lib, og'ir otoimmün kasalliklarga chalingan bemorlar uchun terapiya ishlab chiqish bilan shug'ullanadi. Uning yetakchi klinik bosqichdagi nomzodi, klaseprubart, uzaytirilgan yarim umrga ega, yaxshilangan samaradorlikka va faol C1s komplement oqsiliga yuqori selektivlikka ega bo'lgan monoklonal antitel; va DNTH212, plazmasitoid dendritik hujayra (pDC) BDCA2 ni maqsad qilib olgan bifunksional eritmali oqsil bo'lib, 1-toifa interferon ishlab chiqarishni kamaytiradi, shu bilan birga B hujayra faoliyatini bostirish uchun BAFF/APRILni inhibe qiladi. Dianthus Therapeutics, Inc. 2019 yilda tashkil etilgan va Nyu-York, Nyu-York shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Simrat Randhawa M.B.A., M.D. | Executive VP and Head of R&D |
| Mr. Adam M. Veness Esq. | Senior VP, General Counsel & Secretary |
| Mr. Edward G. Carr | Senior VP & Chief Accounting Officer |
| Mr. Judson Taylor | Senior VP & Head of Technical Operations |
| Mr. Marino Garcia M.B.A. | President, CEO & Director |
| Mr. Ryan Savitz | Executive VP, CFO, Chief Business Officer & Treasurer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | 8-K | dnth-20260505.htm |
| 2026-04-09 | DEF 14A | dnth-20260409.htm |
| 2026-03-26 | 8-K | dnth-20260326.htm |
| 2026-03-12 | 8-K | d43448d8k.htm |
| 2026-03-10 | S-3MEF | d115984ds3mef.htm |
| 2026-03-09 | 10-K | dnth-20251231.htm |
| 2026-01-29 | CORRESP | filename1.htm |
| 2026-01-28 | S-3 | d53438ds3.htm |
| 2026-01-12 | 8-K | dnth-20260112.htm |
| 2025-11-05 | 8-K | dnth-20251105.htm |
| Mr. Scott Nogi M.B.A. | Head of Business Operations |
| Ms. Jennifer Davis Ruff | VP and Head of Investor Relations & Corporate Affairs |
| Ms. Kristina Maximenko | Chief People Officer |
| Ms. Rashieda Gluck | Head of Clinical Development Operations |